Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2025 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

kenvue inc. - KVUE

KVUE

Close Chg Chg %
20.97 0.07 0.31%

Closed Market

21.04

+0.07 (0.31%)

Volume: 7.28M

Last Updated:

Jan 14, 2025, 3:59 PM EDT

Trade Now

Company Overview: kenvue inc. - KVUE

KVUE Key Data

Open

$20.93

 Day Range

20.93 - 21.13

52 Week Range

17.67 - 24.46

 Market Cap

$40.20B

Shares Outstanding

1.92B

 Public Float

1.92B

Beta

1.41

 Rev. Per Employee

N/A

P/E Ratio

37.84

 EPS

$0.56

Yield

386.27%

 Dividend

$0.21

EX-DIVIDEND DATE

Nov 13, 2024

 SHORT INTEREST

N/A

AVERAGE VOLUME

9.70M

  

KVUE Performance

1 Week
 
 0.86%
 
1 Month
 
 -5.31%
 
3 Months
 
 -3.18%
 
1 Year
 
 -2.23%
 
5 Years
 
 N/A
 

KVUE Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 19
Full Ratings ➔

About kenvue inc. - KVUE

Kenvue, Inc. is a consumer health company. It operates through the following business segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment includes cough, cold and allergy, pain care, digestive health, and smoking cessation. The Skin Health and Beauty segment offers face and body care and hair, sun and others. The Essential Health segment focuses on oral care, baby care, women's health and wound care. The company was founded on February 23, 2022 and is headquartered in Skillman, NJ.

KVUE At a Glance

Kenvue, Inc.
199 Grandview Road
Skillman, New Jersey 08558
Phone 1-732-524-0400 Revenue 15.44B
Industry Household/Personal Care Net Income 1.66B
Sector Consumer Non-Durables 2023 Sales Growth 3.443%
Fiscal Year-end 12 / 2024 Employees 22,000
View SEC Filings

KVUE Valuation

P/E Current 37.838
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 24.779
Price to Sales Ratio 2.67
Price to Book Ratio 3.678
Price to Cash Flow Ratio 13.015
Enterprise Value to EBITDA 13.538
Enterprise Value to Sales 3.126
Total Debt to Enterprise Value 0.175

KVUE Efficiency

Revenue/Employee 701,954.545
Income Per Employee 75,636.364
Receivables Turnover 7.45
Total Asset Turnover 0.56

KVUE Liquidity

Current Ratio 1.12
Quick Ratio 0.782
Cash Ratio 0.252

KVUE Profitability

Gross Margin 55.766
Operating Margin 19.031
Pretax Margin 14.181
Net Margin 10.775
Return on Assets 6.033
Return on Equity 10.656
Return on Total Capital 8.473
Return on Invested Capital 8.512

KVUE Capital Structure

Total Debt to Total Equity 75.167
Total Debt to Total Capital 42.912
Total Debt to Total Assets 30.257
Long-Term Debt to Equity 69.432
Long-Term Debt to Total Capital 39.637
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Kenvue Inc. - KVUE

Collapse All in section
All values USD millions. 2020 2021 2022 2023 5-year trend
Sales/Revenue
14.47B 15.04B 14.93B 15.44B
Sales Growth
+1.06% +3.97% -0.76% +3.44%
Cost of Goods Sold (COGS) incl D&A
6.58B 6.56B 6.62B 6.83B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
746.00M 731.00M 644.00M 627.00M
Depreciation
331.00M 317.00M 296.00M 305.00M
Amortization of Intangibles
415.00M 414.00M 348.00M 322.00M
COGS Growth
-0.66% -0.27% +0.88% +3.16%
Gross Income
7.89B 8.48B 8.31B 8.61B
Gross Income Growth
+2.55% +7.51% -2.03% +3.67%
Gross Profit Margin
+54.51% +56.37% +55.64% +55.77%
2020 2021 2022 2023 5-year trend
SG&A Expense
4.91B 5.42B 5.59B 5.67B
Research & Development
320.00M 355.00M 375.00M 399.00M
Other SG&A
4.59B 5.06B 5.21B 5.27B
SGA Growth
-4.70% +10.35% +3.18% +1.52%
Other Operating Expense
- - - -
-
Unusual Expense
66.00M 117.00M 100.00M 481.00M
EBIT after Unusual Expense
2.91B 2.95B 2.62B 2.46B
Non Operating Income/Expense
(3.93B) (21.00M) 18.00M 90.00M
Non-Operating Interest Income
- - - 108.00M
-
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
- - - 358.00M
-
Interest Expense Growth
- - - -
-
Gross Interest Expense
- - - 358.00M
-
Interest Capitalized
- - - -
-
Pretax Income
(1.02B) 2.92B 2.64B 2.19B
Pretax Income Growth
-147.92% +387.89% -9.85% -16.95%
Pretax Margin
-7.02% +19.44% +17.66% +14.18%
Income Tax
(137.00M) 894.00M 550.00M 526.00M
Income Tax - Current - Domestic
308.00M 8.00M 75.00M 266.00M
Income Tax - Current - Foreign
356.00M 318.00M 318.00M 374.00M
Income Tax - Deferred - Domestic
(741.00M) 627.00M 205.00M (39.00M)
Income Tax - Deferred - Foreign
(60.00M) (59.00M) (48.00M) (75.00M)
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(879.00M) 2.03B 2.09B 1.66B
Minority Interest Expense
- - - -
-
Net Income
(879.00M) 2.03B 2.09B 1.66B
Net Income Growth
-161.25% +331.06% +2.76% -20.27%
Net Margin Growth
-6.08% +13.50% +13.98% +10.78%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(879.00M) 2.03B 2.09B 1.66B
Preferred Dividends
- - - -
-
Net Income Available to Common
(879.00M) 2.03B 2.09B 1.66B
EPS (Basic)
-0.4653 1.0752 1.1048 0.8689
EPS (Basic) Growth
-161.25% +331.08% +2.75% -21.35%
Basic Shares Outstanding
1.89B 1.89B 1.89B 1.92B
EPS (Diluted)
-0.4653 1.0752 1.1048 0.8689
EPS (Diluted) Growth
-161.25% +331.08% +2.75% -21.35%
Diluted Shares Outstanding
1.89B 1.89B 1.89B 1.92B
EBITDA
3.73B 3.79B 3.36B 3.57B
EBITDA Growth
+14.62% +1.85% -11.36% +6.04%
EBITDA Margin
+25.74% +25.22% +22.53% +23.09%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 24.769
Number of Ratings 19 Current Quarters Estimate 0.297
FY Report Date 03 / 2025 Current Year's Estimate 1.215
Last Quarter’s Earnings 0.258 Median PE on CY Estimate N/A
Year Ago Earnings 1.143 Next Fiscal Year Estimate 1.301
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 10 9 14 12
Mean Estimate 0.30 0.33 1.21 1.30
High Estimates 0.31 0.33 1.25 1.34
Low Estimate 0.28 0.32 1.18 1.25
Coefficient of Variance 2.92 1.47 1.86 2.30

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 5 4 5
OVERWEIGHT 1 1 2
HOLD 13 14 10
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Overweight Hold Overweight

Insider Actions for Kenvue Inc. - KVUE

Date Name Shares Transaction Value
Jun 6, 2024 Russell Dyer Chief Corp. Affairs Officer 7,796 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jun 6, 2024 Russell Dyer Chief Corp. Affairs Officer 68,389 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 29, 2024 Larry J. Merlo Director 26,739 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 29, 2024 Seemantini Godbole Director 17,189 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 29, 2024 Joseph J. Wolk Director 17,189 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 29, 2024 Tamara Simpkins Franklin Director 17,189 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 29, 2024 Richard E. Allison Director 18,508 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 29, 2024 Peter M. Fasolo Director 17,189 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 29, 2024 Melanie Liddle Healey Director 17,189 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 29, 2024 Michael E. Sneed Director 17,189 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 29, 2024 Vasant M. Prabhu Director 17,189 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 29, 2024 Betsy DeHaas Holden Director 17,189 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 8, 2024 Meredith Stevens Chief Operations Officer 17,840 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 8, 2024 Meredith Stevens Chief Operations Officer 160,481 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 8, 2024 Thibaut Mongon Chief Executive Officer; Director 95,344 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 8, 2024 Jan Meurer Group President, North America 179,810 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 8, 2024 Jan Meurer Group President, North America 19,989 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 8, 2024 Matthew Orlando General Counsel 17,840 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 8, 2024 Matthew Orlando General Counsel 160,481 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 8, 2024 Thibaut Mongon Chief Executive Officer; Director 857,649 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00

Kenvue Inc. in the News